Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Health: Drugs Pricing

House of Lords written question – answered on 10th July 2013.

Alert me about debates like this

Photo of Lord Clement-Jones Lord Clement-Jones Liberal Democrat

To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 24 June (WA 93), how they intend to select which cancer drugs previously considered but not recommended by the National Institute for Health and Care Excellence will be assessed under value-based pricing.

To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 24 June (WA 93), how many cancer drugs previously considered but not recommended by the National Institute for Health and Care Excellence will be assessed under value-based pricing.

To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 24 June (WA 93), whether cancer drugs previously considered but not recommended by the National Institute for Health and Care Excellence which were selected to undergo a value-based pricing assessment will be subject to a different process to new medicines.

To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 24 June (WA 93), what arrangements they intend to put in place to secure patients’ ongoing access during value-based pricing assessments for drugs previously considered but not recommended by the National Institute for Health and Care Excellence.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

As set out in my previous Answer of 24 June 2013, Official Report column WA93, value-based pricing will focus primarily on new medicines. Negotiations with the pharmaceutical industry are ongoing and the scope of the new arrangements, including the medicines to be covered, are matters for these negotiations.

We expect that the National Institute for Health and Care Excellence will apply a single value assessment process to all medicines assessed under value-based pricing.

In the context of developing the new pricing arrangements, we are exploring ways in which patients can continue to benefit from innovative cancer drugs at a cost that represents value to the National Health Service.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.